Vicapsys Life Sciences, Inc. (VICP): Cash & Equivalents
Not updated since 2023-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$9.4K
As of 2023-12-31
$89.6K
As of 2024-09-30
+95.1%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2023-12-31 | $9.4K | -33.2% | 2024-10-21, Balance as of period end |
| 2022-12-31 | $14.1K | -93.5% | 2024-10-21, Balance as of period end |
| 2021-12-31 | $217.3K | n/m | 2023-04-14, Balance as of period end |
| 2020-12-31 | $1.3K | -99.5% | 2022-03-16, Balance as of period end |
| 2019-12-31 | $264.2K | n/a | 2021-09-17, Balance as of period end |